30 results about "Kidney Replacement Therapy" patented technology

A method and device for blood treatments that use fluids such as dialysate and replacement fluid for renal replacement therapy. In an embodiment, fluid is passed either by pump or passively by gravity feed, through a microporous sterilization filter from a fluid source to a replacement fluid container. The latter forms a batch that may be used during treatment. The advantage of forming the batch before treatment is that the rate of filtering needn't match the rate of consumption during treatment. As a result, the sterilization filter can have a small capacity. In another embodiment, a filter is placed immediately prior to the point at which the sterile fluid is consumed by the treatment process. The latter may be used in combination with the former embodiment as a last-chance guarantee of sterility and / or that the fluid is free of air bubbles. It may also be used as the primary means of sterile-filtration.

A method as well as an apparatus is disclosed for determining the efficiency of a currently performed kidney replacement therapy on the dialysis side making use of a dialysis machine which in a first step is operated in a hemodialysis or hemodiafiltration process and in a second step is sequentially changed over to a hemofiltration process or is changed over to a sequential mode in which merely a flow from the blood compartment via the semipermeable membrane to the dialysis fluid compartment of the dialyser is generated in which, according to a third step, a sensor for determining or measuring the concentration at least of uremic toxins in the saturated dialysate or ultra-filtrate which is connected downstream of a dialyser on the dialysis side outputs corresponding measuring signals that are representative of the current concentration at least of uremic toxins in the blood to a calculation or determination unit.

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein / bone morphogenetic protein (OP / BMP) family within the TGF-β superfamily of proteins.

The invention discloses application of danshinolic acid components in preparing pharmaceutical preparations for improving the dialysis rate and filtration rate of protein-bound uremic toxins. The danshinolic acid components include danshinolic acid B, protocatechuic aldehyde, rosmarinic acid, other danshinolic acid monomer components, pharmaceutical preparations containing salviae miltiorrhizae, pharmaceutical preparations containing salviae miltiorrhizae and safflower, and medicine suits with different salviae miltiorrhizae and safflower compatibility proportions. Through screening of a lot of experiments, results show that salviae miltiorrhizae and safflower injections and the danshinolic acid components can remarkably improve the dialysis efficiency of the protein-bound uremic toxins, can remarkably improve the filtering efficiency of the protein-bound uremic toxins, can be developed into auxiliary medicine preparations of in-vitro kidney replacement therapy strategies such as kidney disease dialysis and blood filtering, and have good development and application prospects.

The present disclosure relates to the use of alkaline phosphatases, and in particular improved alkaline phosphatases such as RecAP, for the prevention, treatment, cure, or amelioration of the symptomsof acute kidney injury caused, e.g., by sepsis. The application relates to methods of preserving renal function renal function, shortening the duration of renal replacement therapy, increasing the creatinine clearance, decreasing the risk of death in subjects with sepsis-associate acute kidney injury (SA-AKI) or at risk of SA-AKI.

The invention discloses an intermittent CRRT (Continuous Renal Replacement Therapy) machine capacity balance device. The device comprises a blood circulation system, a first liquid circulation system, and a second liquid circulation system, wherein the blood circulation system consists of a hollow fiber dialyzer, a liquid outlet pipeline, a first circuit interrupting device, a liquid pump, a displacement liquid / dialysis liquid container and a liquid return pipeline; the second liquid circulation system consists of an exogenous displacement liquid / dialysis liquid container, an exogenous displacement liquid / dialysis liquid container liquid outlet pipeline, a second circuit interrupting device, a liquid pump, a displacement liquid / dialysis liquid container, and an exogenous displacement liquid / dialysis liquid container liquid return pipeline; the first liquid circulation system is in contact with the blood circulation system to perform substance exchange; since the volumes are fixed, volume change is not involved in the process of exchange; the first liquid circulation system is separated from the blood system, and is connected to the second liquid system to perform liquid exchange to be refilled with clean fresh displacement liquid, and then performs solute exchange with the blood system. The process is repeated to fulfill the aim of continuously removing solute.